Integrated Approaches to Pain Control in Liver Cancer Patients Undergoing TACE: A Narrative Scoping Review

Pain management is a critical component of care for patients with liver cancer, particularly those undergoing transarterial chemoembolization (TACE), a common interventional procedure for treating hepatocellular carcinoma (HCC). While TACE is effective in controlling tumor growth, it can lead to significant post-procedural pain due to ischemic injury, inflammation, and liver tissue damage. This narrative scoping review explores integrated approaches to pain control in liver cancer patients undergoing TACE, examining pharmacological, interventional, and multidisciplinary strategies to optimize pain relief and enhance overall quality of life. We examine current pain management protocols, focusing on the role of opioids, non-opioid analgesics, and adjunct therapies such as local anesthetics and nerve blocks. Additionally, we explore the emerging use of targeted therapies and immunotherapies in conjunction with TACE, as well as the potential benefits of integrative approaches like acupuncture, physical therapy, and psychosocial interventions in managing pain. The review also considers the challenges of balancing effective pain relief with the risk of side effects, especially in patients with liver dysfunction, comorbidities, and concerns related to opioid use. We further discuss the role of advanced monitoring techniques, including patient-reported outcome measures (PROMs) and multimodal analgesia protocols, to assess pain levels and tailor treatment plans. Given the heterogeneity of patients with liver cancer, the review highlights the importance of personalized care approaches that take into account individual pain thresholds, the stage of the disease, and the goals of treatment. Finally, we explore the role of healthcare teams in delivering comprehensive pain management, emphasizing the need for coordination between oncologists, interventional radiologists, pain specialists, and palliative care providers. In conclusion, integrated pain management approaches, combining pharmacological, interventional, and holistic strategies, are essential for improving the quality of life of liver cancer patients undergoing TACE. Continued research into optimizing pain control and reducing complications associated with analgesic therapies will help ensure better patient outcomes in this vulnerable population.